Table 4.

Clinical efficacy of plerixafor in cancer patients with multiple myeloma or non-Hodgkin’s lymphoma.

Disease	Treatment	Primary outcome*	Efficacy	Phase 3 study	Ref.
Multiple myeloma	Plerixafor plus G-CSF	≥2 × 106 CD34 + cells/kg	141/148 (95.3%)	Study 3102	[85]
		≥6 × 106 CD34 + cells/kg	112/148 (75.7%)
	Placebo plus G-CSF	≥2 × 106 CD34 + cells/kg	136/154 (88.3%)
		≥6 × 106 CD34 + cells/kg	79/154 (51.3%)
non-Hodgkin’s lymphoma	Plerixafor plus G-CSF	≥2 × 106 CD34 + cells/kg	130/150 (86.7%)	Study 3101	[83]
			44/50 (88%)	NCT01767714	[84]
		≥5 × 106 CD34 + cells/kg	89/150 (59.3%)	Study 3101	[83]
			31/50 (62%)	NCT01767714	[84]
	Placebo plus G-CSF	≥2 × 106 CD34 + cells/kg	70/148 (47.3%)	Study 3101	[83]
			33/50 (66%)	NCT01767714	[84]
		≥5 × 106 CD34 + cells/kg	29/148 (19.6%)	Study 3101	[83]
			10/50 (20%)	NCT01767714	[84]

*: Peripheral stem cell collection was conducted within 4 apheresis sessions.